| __timestamp | ADMA Biologics, Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4823869 | 5496000 |
| Thursday, January 1, 2015 | 6745968 | 9786000 |
| Friday, January 1, 2016 | 8494742 | 6792000 |
| Sunday, January 1, 2017 | 18092835 | 7313000 |
| Monday, January 1, 2018 | 22502922 | 8382000 |
| Tuesday, January 1, 2019 | 25910757 | 10803000 |
| Wednesday, January 1, 2020 | 35050817 | 12944000 |
| Friday, January 1, 2021 | 42896889 | 21967000 |
| Saturday, January 1, 2022 | 52458024 | 32810000 |
| Sunday, January 1, 2023 | 59020000 | 46542000 |
Cracking the code
In the competitive landscape of biotechnology, understanding spending patterns is crucial. Over the past decade, ADMA Biologics, Inc. and Xenon Pharmaceuticals Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, ADMA Biologics increased its SG&A spending by over 1,100%, peaking at nearly $59 million in 2023. In contrast, Xenon Pharmaceuticals saw a more moderate rise of approximately 750%, reaching around $46 million in the same year. This divergence highlights ADMA's aggressive expansion strategy compared to Xenon's more conservative approach. Notably, both companies experienced significant growth in SG&A expenses post-2020, reflecting broader industry trends towards increased operational investments. These insights provide a window into the strategic priorities of these biotech firms, offering valuable lessons for stakeholders and investors alike.
Selling, General, and Administrative Costs: Vertex Pharmaceuticals Incorporated vs ADMA Biologics, Inc.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Xenon Pharmaceuticals Inc.
ADMA Biologics, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Research and Development Investment: ADMA Biologics, Inc. vs Xenon Pharmaceuticals Inc.
Selling, General, and Administrative Costs: ADMA Biologics, Inc. vs HUTCHMED (China) Limited
Comparing SG&A Expenses: ADMA Biologics, Inc. vs Celldex Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Apellis Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.
Who Optimizes SG&A Costs Better? Viking Therapeutics, Inc. or Xenon Pharmaceuticals Inc.
Who Optimizes SG&A Costs Better? Xenon Pharmaceuticals Inc. or ACADIA Pharmaceuticals Inc.
Selling, General, and Administrative Costs: Xenon Pharmaceuticals Inc. vs Protagonist Therapeutics, Inc.
Selling, General, and Administrative Costs: Xenon Pharmaceuticals Inc. vs Xencor, Inc.
Xenon Pharmaceuticals Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?